Search Results - "Shu, Yamin"
-
1
Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
Published in CNS neuroscience & therapeutics (01-09-2023)“…Objective Quetiapine, an atypical second‐generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to…”
Get full text
Journal Article -
2
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
Published in Scientific reports (29-11-2022)“…Niraparib was approved for the treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube and primary peritoneal cancer. The authors…”
Get full text
Journal Article -
3
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Published in BMC cancer (11-08-2023)“…Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer…”
Get full text
Journal Article -
4
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Published in Scientific reports (15-11-2022)“…Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug…”
Get full text
Journal Article -
5
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
Published in PloS one (07-12-2022)“…Venetoclax (VEN) is the first selective small molecule Bcl-2 inhibitor approved by FDA and used in adult chronic lymphocytic leukemia (CLL), small lymphocytic…”
Get full text
Journal Article -
6
Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
Published in Frontiers in oncology (01-12-2021)“…The purpose of this cost-effectiveness analysis was to estimate the effects of adding camrelizumab to standard chemotherapy as the first-line treatment in…”
Get full text
Journal Article -
7
Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
Published in Frontiers in immunology (15-05-2023)“…Risankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits IL-23, is currently approved for the treatment of moderate-to-severe plaque…”
Get full text
Journal Article -
8
Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China
Published in Frontiers in oncology (20-04-2022)“…The purpose of this study was to evaluate the cost-effectiveness of nivolumab plus chemotherapy vs. chemotherapy as first-line therapy in patients with…”
Get full text
Journal Article -
9
Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database
Published in Frontiers in pharmacology (06-09-2022)“…Objective: The objective of this study was to scientifically and systematically explore the association between fluoroquinolones (ciprofloxacin, levofloxacin,…”
Get full text
Journal Article -
10
Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
Published in Frontiers in immunology (23-01-2023)“…Sintilimab plus chemotherapy significantly prolongs overall survival (OS) for patients with advanced or metastatic oesophageal squamous cell carcinoma (OSCC)…”
Get full text
Journal Article -
11
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
Published in PloS one (07-12-2022)“…Background Venetoclax (VEN) is the first selective small molecule Bcl-2 inhibitor approved by FDA and used in adult chronic lymphocytic leukemia (CLL), small…”
Get full text
Journal Article -
12
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Published in Frontiers in public health (20-10-2022)“…Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM) and chronic weight management in obesity or overweight adults. However, real-world…”
Get full text
Journal Article -
13
Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
Published in Cancer medicine (Malden, MA) (01-02-2023)“…Objective Poly ADP‐ribose polymerase inhibitors (PARPis) have significantly improved clinical effects in gynecological oncology. However, PARPis could also…”
Get full text
Journal Article -
14
Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
Published in Pharmaceuticals (Basel, Switzerland) (05-08-2024)“…Adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult rheumatoid arthritis (RA), and subsequently approved for…”
Get full text
Journal Article -
15
Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system
Published in Heliyon (15-05-2024)“…Sotorasib has been approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Due…”
Get full text
Journal Article -
16
Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
Published in Frontiers in pharmacology (12-08-2022)“…Objective: The aim of this study was to investigate the cost-effectiveness of olaparib as the maintenance therapy in patients with platinum-sensitive relapsed…”
Get full text
Journal Article -
17
Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
Published in Frontiers in pharmacology (09-07-2024)“…This study aimed to explore the neurological adverse events of oxaliplatin through the Food and Drug Administration Adverse Event Reporting System (FAERS)…”
Get full text
Journal Article -
18
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
Published in Frontiers in pharmacology (20-09-2022)“…Objective: The purpose of this study was to estimate the cost-effectiveness of osimertinib for the first-line treatment of patients with EGFR-mutated advanced…”
Get full text
Journal Article -
19
Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
Published in Frontiers in pharmacology (08-06-2022)“…Purpose: Secukinumab was approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the long-term safety of secukinumab…”
Get full text
Journal Article -
20
A sensitive and rapid radiolabelling method for the in vivo pharmacokinetic study of lentinan
Published in Food & function (20-06-2018)“…The aim of this study is to establish a rapid and sensitive method for detecting lentinan (LNT) in biosamples and to evaluate the pharmacokinetics of LNT in…”
Get more information
Journal Article